Antiphospholipid Antibodies and Renal Involvement

被引:26
作者
Gigante, Antonietta [1 ]
Gasperini, Maria Ludovica [2 ]
Cianci, Rosario
Barbano, Biagio
Giannakakis, Konstantinos [3 ]
Di Donato, Domenico
Fuiano, Giorgio [4 ]
Amoroso, Antonio [2 ]
机构
[1] Univ Roma La Sapienza, Fac Med 1, Dept Nephrol, IT-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dept Clin Med, IT-00185 Rome, Italy
[3] Univ Roma La Sapienza, Dept Expt Med & Pathol, IT-00185 Rome, Italy
[4] Magna Graecia Univ Catanzaro, Dept Nephrol, Catanzaro, Italy
关键词
Antiphospholipid antibodies; Antiphospholipid syndrome; Systemic lupus erythematosus nephritis; Antiphospholipid syndrome nephropathy; INTERNATIONAL CONSENSUS STATEMENT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LOW-DENSITY-LIPOPROTEIN; ANTICARDIOLIPIN ANTIBODIES; ARTERY STENOSIS; CLASSIFICATION CRITERIA; SYNDROME NEPHROPATHY; HUGHES SYNDROME; THROMBOSIS; DISEASE;
D O I
10.1159/000235941
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Antiphospholipid antibodies are a heterogeneous group of autoantibodies associated with the hypercoagulable state affecting all vascular districts with thrombosis named antiphospholipid syndrome (APS). APS is an autoimmune disease with multifactorial etiology that includes cellular, molecular, genetic and pathogenic mechanisms. The APS clinical features are a combination of arterial and/or venous thrombosis, hematological events, recurrent fetal losses, neurological disorders and intra-abdominal manifestations. The renal involvement is associated with both primary and secondary APS. Clinical features include hypertension, renal artery stenosis, thrombotic microangiopathy and other histological manifestations of the nephropathy (APSN), venous renal thrombosis, APSN in the course of systemic lupus erythematosus and renal failure. APSN is an independent risk factor that should be included in the classification criteria for definite APS with characteristic clinical and histological features. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:405 / 412
页数:8
相关论文
共 42 条
  • [1] Asherson R., 1996, ANTIPHOSPHOLIPID SYN, P3
  • [2] Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: An overview
    Atanassova, Penka A.
    [J]. YONSEI MEDICAL JOURNAL, 2007, 48 (06) : 901 - 926
  • [3] Atsumi T, 1998, ARTHRITIS RHEUM, V41, P800, DOI 10.1002/1529-0131(199805)41:5<800::AID-ART5>3.0.CO
  • [4] 2-J
  • [5] Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis
    Bhandari, S
    Harnden, P
    Brownjohn, AM
    Turney, JH
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (06): : 401 - 409
  • [6] Mortality in the catastrophic antiphospholipid syndrome - Causes of death and prognostic factors in a series of 250 patients
    Bucciarelli, Silvia
    Espinosa, Gerard
    Cervera, Ricard
    Erkan, Doruk
    Gomez-Puerta, Jose A.
    Ramos-Casals, Manuel
    Font, Josep
    Asherson, Ronald A.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (08): : 2568 - 2576
  • [7] Which are the best biological markers of the antiphospholipid syndrome?
    Carreras, LO
    Forastiero, RR
    Martinuzzo, ME
    [J]. JOURNAL OF AUTOIMMUNITY, 2000, 15 (02) : 163 - 172
  • [8] Lessons from the "Euro-Phospholipid" project
    Cervera, Ricard
    [J]. AUTOIMMUNITY REVIEWS, 2008, 7 (03) : 174 - 178
  • [9] ARE ANTIPHOSPHOLIPID ANTIBODIES CLINICALLY RELEVANT IN DIALYSIS PATIENTS
    CHEW, SL
    LINS, RL
    DAELEMANS, R
    ZACHEE, P
    DECLERCK, LS
    VERMYLEN, J
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (12) : 1194 - 1198
  • [10] Rapidly progressive renal failure in a 35-year-old woman with systemic lupus erythematosus. Antiphospholipid-antibody syndrome, catastrophic, with renal thrombotic microangiopathy due to systemic lupus erythematosus. Lupus nephritis, mild.
    Coggins, CH
    Bazari, H
    McCluskey, RT
    Spragg, D
    Smith, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (15) : 1152 - 1158